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Abstract 
There has been considerable progress in the development of tools that assess cough.  The 
Visual Analogue Scale for cough severity is widely used and it is brief and practical for use 
in the clinic.   The Leicester Cough Questionnaire (LCQ) and the Cough-specific Quality of 
Life Questionnaire (CQLQ) are the most widely used health status questionnaires for adult 
patients with chronic cough.   They are well validated for assessing the impact of cough.  
Cough can be assessed objectively with challenge tests that measure the sensitivity of the 
cough reflex.   Cough challenge tests are better used to determine the mechanism of action of 
therapy, rather than efficacy.   Cough frequency monitoring is the preferred tool to assess 
cough objectively, and they are increasingly being used as primary end-points in clinical 
trials.   The most widely used cough monitors are the Leicester Cough Monitor (LCM) and 
VitaloJak.  They are ambulatory devices that consist of a microphone and recording device.  
Cough frequency monitors do not reflect the intensity or the impact of cough; hence their 
relationship with subjective measures of cough is weak.   Cough should therefore be assessed 
with a combination of subjective and objective tools.   There is a paucity of studies that have 
investigated the minimal important difference of cough frequency monitors; this deserves 
further investigation. 
 
Keywords: cough, cough intensity, monitoring, measurement, quality of life 
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Introduction 
Cough is associated with significant physical and psychological morbidity.(1)    An 
assessment of cough severity is important in the clinic because it is used to evaluate the 
response to trials of therapy.(2)     It is also important in clinical trials that evaluate the 
efficacy of anti-tussive medications.(3)     The severity of cough can be measured by several 
methods; symptom severity, frequency, intensity and impact on quality of life.   A number of 
validated tools are now available to assess cough (Table 1).   A combined subjective and 
objective assessment is necessary for comprehensive evaluation.(4)    This review article will 
focus on the measurement and monitoring in adult patients with chronic cough. 
 
Visual Analogue Scales  
Visual Analogue Scales (VAS) are widely used for the subjective assessment of cough 
because they are brief and easy to use.(5)  The subject is asked to mark on a 100mm scale 
between ‘no cough’ and ‘the worst cough severity’.  The advantage of VAS is that they 
assess the symptom in isolation and reflect the severity.   They are also freely available.   The 
VAS is likely to be valid for use in research studies.   There is however, a lack of published 
data reporting its validity and the minimal important difference.   The VAS has also been 
evaluated in acute and sub-acute cough.(6;7)  The minimal important difference (MID) has 
been reported to be 17mm in acute cough.(6)  The MID for VAS in chronic cough is likely to 
be similar to that of acute cough in the authors’ opinion but this has not be studied.    The 
VAS is highly responsive to change.(8)  In the authors’ opinion, the use of VAS should be 
encouraged because it is familiar to clinicians, brief and clinically meaningful.   Furthermore, 
similar tools are used effectively in the management of other symptoms such as chest pain.   
The benefits of using the VAS include improved communication between clinicians 
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regarding the severity of cough and documenting longitudinal observations.   The VAS can 
also be used to assess the urge, frequency and intensity of cough.   
 
 
Health Related Quality of Life 
Cough can have a wide-ranging impact on the patient, and is very disruptive.    It can lead to 
physical symptoms such as syncope, chest pain, urine incontinence, vomiting, headache and 
sleep disturbance.   It is associated with psychological morbidity such as anxiety and 
depression and socially it can lead to embarrassment and disruption of activities.   Health-
Related Quality of Life (HRQOL) can be quantified by using specifically designed 
questionnaires.  Their advantage in comparison to VAS scales is that they capture the wider 
impact of cough on the individual.   HRQOL questionnaires provide a structured and 
standardised approach to quantifying health status.   They are well validated for this purpose 
and highly responsive to change.(9)   HRQOL questionnaires can be categorised into generic 
tools, such as the SF-36 or SGRQ (St George’s Respiratory Questionnaire) or disease 
specific. A limitation of generic tools is that they are generally longer questionnaires and 
potentially less responsive to change.    It is advisable to use cough-specific HRQOL 
questionnaires for the assessment of health status in patients with cough.   The two most 
widely used HRQOL questionnaires for adult patients with chronic cough are the Leicester 
Cough Questionnaire (LCQ) and Cough-Specific Quality of Life (CQLQ).(10;11)   For 
children, a recently validated questionnaire is now available, Paediatric Cough – Quality of 
Life Questionnaire (PC-QLQ).(12) 
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Leicester Cough Questionnaire (LCQ) 
The LCQ is a 19-item questionnaire comprising three health domains;   physical, 
psychological and social.(10)   It is brief, easy to use and score.   It was developed using a 
patient-rated importance scale, also known as a clinimetric method.   It was developed for 
patients with chronic cough but has also been validated for patients with Chronic Obstructive 
Pulmonary Disease (COPD), bronchiectasis and acute cough.(13-15)   It is the most widely 
used of all cough HRQOL questionnaires, since 2001.  It has been translated into a wide 
range of languages.   The LCQ has been well validated and has very good internal reliability, 
repeatability and responsiveness.(10)  The minimal important difference in acute and chronic 
cough are 2.0 and 1.3 respectively.(6;15)    The LCQ has been used in clinical trials of 
Erythromycin, Gabapentin, cough suppression physiotherapy and Interferon therapy.  It is 
currently being used in a clinical trial of Transient Receptor Potential Ankyroid Receptor 
Type 1 inhibitor.    
 
Cough-specific Quality of Life Questionnaire (CQLQ) 
The CQLQ is a 28-item questionnaire with 6 domains, developed in the United States of 
America.(11)   It was also developed using clinimetric methodology.   The CQLQ is well 
validated in chronic cough, acute cough and Idiopathic Pulmonary Fibrosis (IPF).  It has good 
internal reliability, repeatability, responsiveness and the minimal important difference in 
chronic cough is 13 units.(16)   It has recently been used in a clinical trial of Esomeprazole in 
chronic cough and Thalidomide in patients with cough associated with IPF.(17;18)   
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Other Subjective Questionnaires  
Cough Severity Score (CSS) 
The CSS is a two-part question referring to symptoms during the day and night time.(19)     
The response scale captures cough frequency, intensity and overall impact.     There is little 
clinical experience with this tool and the minimal important difference has not been reported.   
Further studies of this tool are underway. 
 
Cough Severity Diary (CSD) 
CSD is a brief tool, comprising 7 items.(20)  It was developed using feedback from patients.   
In addition to severity, it captures the impact of cough intensity.  There is, however, little 
clinical experience with this tool.  The minimal important difference has not been studied. 
 
Objective assessment of cough 
There has been significant progress recently in the development of objective tools to assess 
cough.    The clinical use of objective tools is to validate the presence of cough in subjects 
and evaluate the improvement following therapy.      Until the development of cough 
monitors, assessment of cough reflex sensitivity was the only objective method being used.    
The limitation of cough reflex sensitivity measurement is that it only assesses the mechanism 
of cough, not the efficacy from the patient’s perspective.   The recent technological advances 
in recording devices have led to significant achievements in the field of cough detection 
monitoring.  There is general consensus that the assessment of cough frequency is the gold-
standard objective tool.(21)   It is also possible to measure cough intensity with physiological 
measures, but they are invasive, and not practical for the clinical setting.        
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Cough Reflex Sensitivity – the Cough Challenge Test 
The methodology to measure the sensitivity of the cough reflex is, in principle, similar to that 
used to assess bronchial responsiveness with agents such as methacholine.    Cough is 
provoked by the inhalation of nebulised tussive agents, usually capsaicin or citric acid.   
Other tussive agents that can be used include tartaric acid, fog, cinnamaldehyde and 
bradykinin.  The outcome measure is usually expressed as the concentration of tussive agent 
that causes two or five coughs, C2 or C5.     Cough reflex sensitivity assessment is 
reproducible and a responsive measure.(22)    It is frequently used in both animal and human 
research studies.     A major limitation to its use in clinical practice is its inability to 
discriminate patients with cough from healthy subjects.(22)  Another limitation is that 
capsaicin dilutions need to be made frequently due to its instability in solution in contrast to 
other challenge tests such as methacholine. The test also needs to be performed in a ventilated 
room.   The utility of cough reflex sensitivity tests in clinical trials is subsiding because they 
do not consistently reflect the efficacy of therapy from the patient’s perspective.   Its use in 
future is likely to be limited to research studies investigating the mechanism of action of anti-
tussive therapy.  It may be particularly useful in drug development when specific cough 
reflex pathways can be investigated. The challenge for the future is to develop methodology 
that can reliably discriminate healthy subjects from those with cough.   This may be possible 
by using higher concentrations of tussive agents than currently used.(23)    
 
Cough Frequency Monitors 
Cough frequency assessment is considered the gold-standard by many for the objective 
assessment of cough.   Until ten years ago, the development of cough monitors was limited 
by the recording capacity of tape recorders and poor battery life.     The development of MP3 
recorders overcame hardware limitations, and therefore the focus turned to the development 
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of software for automated cough detection.   There has been significant progress in the 
development of automated cough detection software, but with mixed results.   Many cough 
monitors have insufficient accuracy for cough detection, and therefore their use is limited or 
they are not used at all, such as the Hull Automated Cough Monitor, LifeShirt and 
Pulmotrack.(24-26)  A particular challenge has been the discrimination of cough sounds from 
speech and other noise.     Two cough monitoring systems have demonstrated good validity 
and are being used more widely in clinical trials, the Leicester Cough Monitor (LCM) and the 
VitaloJak.   They differ in their approach to cough detection;   the VitaloJak requires manual 
assessment of cough recordings, and the LCM is largely automated.  
 
VitaloJak 
The VitaloJak consists of two microphones (contact and free-field) and a MP3 recorder.(27)    
A condensed version of the recording is assessed manually to listen for cough sounds.   The 
condensed 24-hour cough recording is on average 1.5 hours long.   The accuracy of this 
monitor is dependent on the observer conducting the manual counting and, in experienced 
hands, it is very good.(27)   A limitation of manual assessment is that it is labour-intensive 
and time-consuming, which adds to the cost.   The VitaloJak has largely been used in one 
centre.  A comparison of the characteristics of the VitaloJak and LCM is reported in Table 2.    
The characteristics are remarkably similar, despite the very different approaches to cough 
detection.  
 
Leicester Cough Monitor (LCM):   
The LCM comprises of a free-field microphone and a MP3 recorder.(28)   Cough detection is 
largely automated using specifically designed software.   This involves minor refinement by 
an operator (5 minutes per 24-hour recording).    The sensitivity and specificity for cough 
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detection is very good.(28;29)   The LCM has been used in single and multi-centre clinical 
trials.(30;31)    
 
The relationship between objective cough frequency and subjective measures of cough 
The relationship between objective cough frequency and subjective measures of cough     
such as VAS and HRQOL is weak to moderate.(32)  This reflects the different aspects of 
cough assessed by these tools such as perception vs. actual frequency.  The poor relationship 
does not imply that cough frequency monitoring is inaccurate for the detection of cough.   
The accuracy of automated cough monitors is established by comparison to manually counted 
recordings.(28) 
 
Cough frequency monitors in the clinical setting 
Cough frequency monitors are now sufficiently practical and validated for use in the clinic 
and clinical trials.   The automation of cough monitoring has facilitated this.   Patients with 
chronic cough, cough on average every two minutes in a 24 hour period (Figure 2).   This 
contrasts with healthy subjects who cough on average every thirty minutes. Cough has a 
diurnal pattern in both disease and health states; cough is significantly reduced at night.   In 
patients complaining of cough, the pattern and frequency of cough is very similar irrespective 
of underlying causes such as gastro-oesophageal reflux and cough variant asthma.    In the 
authors’ experience, the frequency of cough in patients with chronic lung diseases such as 
classic asthma, COPD and IPF depends on the prominence of cough as a symptom.    In some 
patients, the frequency can be as high as those with idiopathic chronic cough.   Cough 
monitors are the best tools to discriminate patients with cough from healthy subjects.  
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The utility of cough monitor in clinical practice has not been established.    The severity of 
cough can simply be assessed by asking the patient but disadvantages of this are some 
patients and clinicians may be poor judges of symptom severity.   Cough monitors can 
potentially be used to validate the presence of cough.   They can also be used to quantify the 
response to therapy.     They have been used in the research setting to assess the temporal 
relationship of cough with episodes of gastro-oesophageal reflux; the clinical usefulness of 
this has not been established.(33)   The benefits of cough monitoring technology in the clinic 
need further investigation.  Cough monitors however are considered an important end-point 
in clinical trials.    The strength of cough monitors is their objectivity and that they can 
discriminate healthy subjects from those without cough.    This may be useful for selecting 
patients for clinical trials.    Cough frequency has been reported to be a repeatable measure in 
patients with stable chronic cough.    In contrast, in acute cough, cough frequency is not 
repeatable due to natural recovery.(6)   The rate of improvement in cough frequency may be a 
better measure in such patients. 
 
Cough frequency monitors as a study endpoint 
Cough frequency can be expressed by a range of outcome measures.  For example, absolute 
counts vs. coughs per hour.   Cough can be assessed during daytime, night time or 24 hours.  
It is perhaps better to express change in cough frequency as a percentage or fold change, 
rather than absolute change, since it has a wide range.     An advantage of using cough 
frequency measures to determine the sample size of studies is that considerably fewer 
subjects are required in comparison to subjective outcome measures, such as HRQOL.     This 
is due to the comparatively larger change in cough frequency required to demonstrate a 
minimal important difference.(6)   For example, in acute cough, the minimal important 
difference for cough frequency has been reported as a 54% reduction.(6)   
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Cough Intensity 
The intensity of cough may also be relevant to the impact on an individual, in addition to the 
frequency.  Little is known about cough intensity and its importance to patients.  It can be 
assessed subjectively with VAS or objectively with physiological measures such as cough 
flow, oesophageal pressure or electromyography.  Flow is the most practical physiological 
measure since it is non-invasive and relatively easy to perform.   However, its limitation is 
that it is not ideal for continuous monitoring in an ambulatory setting.     It may be possible to 
assess cough intensity with sound.(34)   Further studies are needed to determine whether 
cough sound is a valid measure of cough intensity, its relationship with subjective measures 
and clinical relevance.   
 
Conclusion 
A number of tools are now available to assess cough.  It is likely that a combination of 
subjective and objective assessment is necessary to assess cough comprehensively since each 
tool assesses very different aspects.  For subjective assessment, the VAS is ideal for use in 
the clinic since it is practical, and it can be used to communicate the severity of cough to 
other clinicians and for longitudinal observation.   It is also ideal for use in clinical trials.   
The VAS should be complemented by HRQOL assessment to assess impact.   HRQOL 
questionnaires for cough are the most validated of all cough assessment tools.   The LCQ and 
the CQLQ are the most widely used for adult patients with chronic cough.   It is arguable that 
the primary outcome measure of clinical trials should be objective, and cough frequency 
monitors are best placed for this.   Cough frequency monitors are increasingly being used in 
clinical trials.    The clinical experience of using cough monitors to date is that they are 
practical and valid.   They should always be complemented by assessment of HRQOL since a 
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reduction in objective cough frequency without subjective improvement would not be 
considered clinically important.  Further work is necessary in a number of areas to improve 
the utility of cough assessment tools. The investigation of the minimal important difference 
and more precise sample size estimations are good examples. The assessment of cough in 
chronic lung disease such as chronic obstructive pulmonary disease and idiopathic pulmonary 
fibrosis is likely to be very fruitful.    
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Table 1. Cough measurement tools. 
 
 
SYMPTOMS 
 
HRQOL 
 
OBJECTIVE 
 
Cough 
Reflex 
Sensitivity 
 
Cough 
Monitors 
 
VAS 
CSS 
CSD 
 
LCQ 
CQLQ 
 
Capsaicin 
Citric Acid 
Fog 
Tartaric acid 
 
 
LCM 
VitaloJak 
 
 
HRQOL: health related quality of life, VAS: visual analogue scales, CSS: cough severity 
score, CSD: cough severity diary, LCQ: Leicester Cough Questionnaire, CQLQ: cough 
specific quality of life questionnaire, LCM: Leicester Cough Monitor. 
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Table 2. A comparison of the characteristics of Leicester Cough Monitor vs. VitaloJak 
 
 
 
 
 
Leicester Cough Monitor 
(LCM) 
 
 
VitaloJak 
 
Hardware 
 
 
 
External microphone and 
MP3 recorder 
 
External microphone and 
MP3 recorder 
 
Recording duration 
 
 
24 Hours 
 
24 Hours 
 
Analysis method 
 
 
Automated software 
 
Manual 
 
Operator time                  
(mean/ per 24-hr recording) 
(6;27) 
 
 
5 min 
 
 
87 min 
 
 
Association with subjective 
measure (HRQOL, LCQ) 
(correlation coefficient)(32;35)  
 
 
-0.60 
 
-0.62 
 
Cough frequency (per hr) 
 
Healthy subjects (29;36) 
Chronic cough (29;37) 
Acute cough URTI (6;38) 
COPD (29;36) 
 
 
 
 
  1 
  20 
  15 
  9 
 
 
 
1 
17 
12 
9 
 
 
LCQ: Leicester Cough Questionnaire (patients with chronic cough); HQROL: health related 
quality of life; COPD: chronic obstructive pulmonary disease; URTI: upper respiratory tract 
infection. Cough frequency recordings per 24-hours. 
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Figure 1. 24 Hour frequency in a patient with chronic cough. 
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